Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 4/20 | 0.43 |
| ▸ | GABRD | O14764 | 4/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.43 |
| ▸ | GABRE | P78334 | 4/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Alanine SCHEMBL43623 | 1.00 | — | — | |
| D-Alanine SCHEMBL614024 | 1.00 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL10723495 | 1.00 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL1332110 | 1.00 | — | — | |
| Alanine SCHEMBL31 | 1.00 | — | — | |
| Alanine SCHEMBL2784274 | 1.00 | — | — | |
| Alanine SCHEMBL14764702 | 1.00 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| D-Alanine SCHEMBL2027760 | 1.00 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL452350 | 1.00 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| D-Alanine SCHEMBL31040666 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| WO-2026077418-A9 | ISOINDOLINE COMPOUND CONTAINING PHENYLETHOXYALKYLENEAMINE STRUCTURE, CONJUGATE THEREOF, AND USE THEREOF | 上海海雁医药科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| EP-4703389-A1 | ANTI-PTK7 ANTIBODY AND USES THEREOF | MabCare Therapeutics (CN) | 2026-03-04 | — | — | EP | claimed |
| WO-2026044039-A2 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-02-26 | — | — | WO | claimed |
| EP-4696714-A1 | PREPARATION METHOD FOR NANOBODY TARGETING TISSUE FACTOR AND CONJUGATE AND USE THEREOF | Fudan University (CN) | 2026-02-18 | — | — | EP | claimed |
| US-12534541-B2 | Anti-PTK7 antibody and uses thereof | MABCARE THERAPEUTICS (CN) | 2026-01-27 | — | — | US | claimed |
| EP-4680285-A1 | SUBCUTANEOUSLY ADMINISTERED ANTIBODY-DRUG CONJUGATES FOR USE IN CANCER TREATMENT | Heidelberg Pharma Research GmbH (DE) | 2026-01-21 | — | — | EP | claimed |
| US-12514928-B2 | Herboxidiene antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-01-06 | — | — | US | claimed |
| US-12514926-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-01-06 | — | — | US | claimed |
| US-20250382376-A1 | NANOBODY AND NANOBODY-DRUG CONJUGATE TARGETING CD73, METHOD FOR PREPARING SAME, AND USE THEREOF | UNIV FUDAN (CN) | 2025-12-18 | — | — | US | claimed |
| EP-1082120-A1 | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE | OSI Pharmaceuticals, Inc. (US) | 2001-03-14 | — | — | EP | claimed |
| WO-1999062518-A1 | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE | OSI PHARMACEUTICALS, INC. (US) | 1999-12-09 | — | — | WO | claimed |
| US-5972677-A | ALLOW FOR INTERNAL INITIATION OF MRNA CAP-INDEPENDENT TRANSLATION. | Tischfield, J. | 1999-10-26 | — | — | US | claimed |
| WO-1998046996-A9 | LCK SERINE PHOSPHORYLATION ASSAY FOR T-CELL ACTIVATION AND ACTIVATION-INDUCED CELL DEATH | ROBARTS JOHN P RES INST (CA) | 1999-05-06 | — | — | WO | claimed |
| WO-1998046996-A2 | LCK SERINE PHOSPHORYLATION ASSAY FOR T-CELL ACTIVATION AND ACTIVATION-INDUCED CELL DEATH | THE JOHN P. ROBARTS RESEARCH INSTITUTE (CA) | 1998-10-22 | — | — | WO | claimed |
| US-5612194-A | Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1997-03-18 | — | — | US | claimed |
| US-5266465-A | Anticoagulants | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1993-11-30 | — | — | US | claimed |
| US-5252725-A | α-1-antichymotrypsin, analogues and methods of production | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1993-10-12 | — | — | US | claimed |
| US-5079336-A | α-1-antichymotrypsin, analogues and methods of production | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1992-01-07 | — | — | US | claimed |
| EP-0199432-A2 | Assaying method for primary amines using aromatic dialdehydes | OREAD LABORATORIES, INC. (US) | 1986-10-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534541-B2 | Anti-PTK7 antibody and uses thereof | LTK, IGSF11, IGLV6-57 | SLC7A5 2128/4885TP53 1704/4885SLC1A3 1731/4885 |
| US-20250382376-A1 | NANOBODY AND NANOBODY-DRUG CONJUGATE TARGETING CD73, METHOD FOR PREPARING SAME, AND USE THEREOF | ENTPD1, ENTPD5, NT5E | SLC7A5 1810/4885TP53 615/4885SLC1A3 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.